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Clozapine can cause severe adverse effects yet it is associ-
ated with reduced mortality risk. We test the hypothesis 
this association is due to increased clinical monitoring and 
investigate risk of premature mortality from natural causes. 
We identified 14 754 individuals (879 deaths) with serious 
mental illness (SMI) including schizophrenia, schizoaffec-
tive and bipolar disorders aged ≥ 15 years in a large spe-
cialist mental healthcare case register linked to national 
mortality tracing. In this cohort study we modeled the 
effect of clozapine on mortality over a 5-year period (2007–
2011) using Cox regression. Individuals prescribed clozap-
ine had more severe psychopathology and poorer functional 
status. Many of the exposures associated with clozapine 
use were themselves risk factors for increased mortality. 
However, we identified a strong association between being 
prescribed clozapine and lower mortality which persisted 
after controlling for a broad range of potential confounders 
including clinical monitoring and markers of disease sever-
ity (adjusted hazard ratio 0.4; 95% CI 0.2–0.7; p = .001). 
This association remained after restricting the sample to 
those with a diagnosis of schizophrenia or those taking 
antipsychotics and after using propensity scores to reduce 
the impact of confounding by indication. Among individu-
als with SMI, those prescribed clozapine had a reduced risk 
of mortality due to both natural and unnatural causes. We 
found no evidence to indicate that lower mortality associ-
ated with clozapine in SMI was due to increased clinical 
monitoring or confounding factors. This is the first study to 
report an association between clozapine and reduced risk 
of mortality from natural causes.
Key words:  clozapine/ mortality/ clinician contact/ 
schizophrenia/ schizoaffective disorder/ bipolar affective 
disorder
Introduction
Individuals with serious mental illness (SMI), including 
schizophrenia, schizoaffective and bipolar disorder have 
1.5–2.5 times the mortality risk of the general popula-
tion1–3 and a 10–20 year reduction in life expectancy4 with 
the majority of the excess deaths being due to natural 
causes.1 Difficulty performing activities of daily living, 
substance misuse, adverse lifestyle choices, psychopathol-
ogy and medications appear to contribute to the elevated 
mortality rate.5–7
Antipsychotic medications, the mainstay of SMI treat-
ment, are associated with increased risk of physical mor-
bidity and premature death in individuals with SMI.8–10 
Importantly, mortality risk to these individuals may vary 
between the antipsychotics they are prescribed.11 A number 
of investigations, including several large scale cohort stud-
ies, have reported that clozapine has the lowest risk of all-
cause mortality and suicide specifically compared to other 
antipsychotics.12–15 Clozapine is highly effective; however, its 
use is restricted owing to safety concerns regarding the risk 
of agranulocytosis, seizures, myocarditis and other adverse 
cardiovascular/respiratory effects in patients prescribed 
this antipsychotic.16,17 Consequently, clozapine can only 
be prescribed to individuals who receive at least monthly 
blood monitoring (with no signs of agranulocytosis) and is 
restricted to individuals with treatment-resistant SMI.
Despite treatment guidelines, substantial delays to 
clozapine initiation remain and antipsychotic polyphar-
macy and high doses are commonly used prior to clo-
zapine.18 There is evidence that clozapine is under used, 
with calls for restrictions on clozapine to be reevalu-
ated.15,18 However, clozapine is the only antipsychotic 
where routine specialist clinical contact is mandated. 
Frequent mental health assessments may be protective 
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against mortality in patients with schizophrenia19 so it 
is possible that monitoring rather than clozapine per se 
reduces premature mortality risk in these patients. Few 
studies investigating antipsychotic use and all-cause mor-
tality have controlled for clinical contact; those that do 
have failed to differentiate between clozapine and other 
antipsychotics,19 or else have only controlled for hospital-
izations rather than all face-to-face clinical contact.15 In 
addition, there is a prevailing view that clozapine confers 
protection on overall mortality through preventing sui-
cide in individuals with SMI,15,20 yet no adequately pow-
ered studies have examined clozapine’s associations with 
natural causes of mortality in this patient group. In this 
investigation we draw on data from a large electronic case 
register to test the hypotheses that the protective effect of 
clozapine on mortality in individuals with SMI is due to 
more frequent clinical monitoring and that clozapine is 
associated with lower risk of mortality from natural as 
well as unnatural causes in these patients.
Methods
Setting
This study used data from the South London and 
Maudsley NHS Foundation Trust (SLAM) Case 
Register; a large, anonymized, electronic mental health 
records database (described elsewhere)21 which has been 
used extensively in previous research.5,22,23 In the United 
Kingdom, mental health services are provided accord-
ing to defined geographic catchment areas under the 
National Health Service (NHS). SLAM delivers all 
aspects of specialist mental healthcare to approximately 
1.2 million residents of 4 London boroughs (Lambeth, 
Southwark, Lewisham, and Croydon). Since 2006, fully 
electronic clinical records have been maintained by all 
SLAM services. The Clinical Record Interactive Search 
(CRIS) system allows researchers to search on structured 
data and free-text fields for the 200 000 plus individuals 
represented in the system.
Ethics statement
CRIS was approved as an anonymised data resource 
for secondary analysis by Oxfordshire Research Ethics 
Committee C (08/H0606/71) and governance is provided 
for all projects and dissemination through a patient-led 
oversight committee. A  linkage with death certification 
was further approved by the same committee.
Inclusion criteria
The cohort comprised individuals who had received an 
SMI diagnosis (WHO ICD-10 codes: F20, F25, F31)24 
during an observation period from January 1, 2007 to 
December 31, 2011 inclusive, and who were 15  years 
or older at the time of their first SMI diagnosis in this 
period. Those individuals who had been prescribed clo-
zapine prior to entering the observation period were 
excluded. Consequently, the analyses compared individu-
als who were newly prescribed clozapine against those 
with no evidence of this agent being prescribed. As men-
tioned above, electronic clinical records have been main-
tained by all SLAM services since 2006. Consequently 
we were able to search over a minimum of 12  months 
prior to the start of the observation period for clozapine 
prescriptions. However, we also searched earlier records 
where these were represented in the SLAM electronic 
health record database. Diagnosis and medication data 
within free-text fields in the SLAM Case Register were 
extracted using natural language processing applications 
(described below) which supplemented information in 
structured fields.
Data extraction from free-text fields
Applications for extracting information from free-text 
fields were built using Generalized Architecture for Text 
Engineering (GATE). GATE is a widely used program 
which provides a suite of tools to assist with natural lan-
guage processing tasks such as information extraction 
from clinical notes. These applications were designed to 
extract data from the free text taking into account the 
linguistic context and validated (against human raters). 
These applications go well beyond a basic key word 
search. For example, natural language processing makes 
it possible to differentiate between a current prescription 
of clozapine and instances where the word clozapine is 
used in other contexts. We tested precision (positive pre-
dictive value) of the application for extracting/coding 
medications data on randomly selected instances where 
the application coded the patient as being prescribed clo-
zapine (n = 279). We then determined if  this was correct 
by manually searching through the underlying document. 
To determine recall (sensitivity) we extracted a random set 
of documents (n = 200) that contained the word clozap-
ine, read these documents to ascertain whether the patient 
was actually prescribed clozapine, then determined if  this 
was in agreement with the coding performed by the natu-
ral language processing application.
Main outcome measure
Mortality (all-cause/cause-specific) during the obser-
vation period (2007–2011, inclusive) was determined 
through routine nationwide mortality tracing linked to 
the electronic health record.2 In the United Kingdom, all 
death certifications are linked to NHS number (a unique 
identifier for UK NHS medical records). Healthcare pro-
viders are required by law to keep these records up to date. 
NHS numbers for all previous and current SLAM con-
tacts are checked monthly against the national mortality 
database and deaths electronically flagged. Moreover, a 
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linkage to additional data derived from death certificates 
allowed us to distinguish natural from unnatural causes 
of mortality where ICD-10 codes S00-T98 (injury, poison-
ing and certain other consequences of external causes), 
V01-Y98 (external causes of morbidity and mortality) 
and U509 (death from injury or poisoning event await-
ing determination) were classified as unnatural mortality 
with the remaining codes classified as natural mortality.
Exposure variables
People who took clozapine at any stage during their fol-
low-up period were designated as the exposed group. The 
follow-up period commenced from the first diagnosis of 
SMI during the observation period through to the cen-
sor date (last day of the observation period–December 
31, 2011) or the patient’s death, whichever occurred ear-
liest. In addition, those who had been prescribed any 
type of antipsychotic during follow-up were identified. 
Prescribing data were obtained from the SLAM phar-
macy dispensing database and structured medications 
fields in the source electronic health record, as well as 
from free text using GATE as previously described. Using 
these data we calculated the duration over which patients 
were prescribed clozapine during the observation period.
We defined clinical monitoring as the proportion of 
days on which each individual with SMI received face to 
face clinical contact during follow-up. Any day on which 
a service user was an inpatient (for some or all of that day) 
or had engaged in face to face clinical interaction with a 
mental health professional was counted as a one clinically 
monitored day. The clinical monitoring was recorded as 
a percentage (a continuous variable and in tertiles) rather 
than the absolute number of days to account for varying 
follow-up periods. In addition we adjusted for inpatient 
and outpatient contact as separate covariates.
Since the introduction of Mental Health Act 2007, 
patients compulsorily detained in hospital in England 
and Wales for treatment may, on discharge, be placed on 
a supervised community treatment order (CTO), requir-
ing them to comply with certain conditions related to 
their mental health treatment. One of the main indica-
tors for CTOs are to enhance adherence to medications.25 
Similarly, delivering medications as long acting injectable 
(LAI) or depot is indicated when individuals have dif-
ficulty adhering to oral medication regimes. We defined 
CTOs or having received any medication via LAI (prior 
to or during follow-up) as a marker of potential nonad-
herence with the view that those with poor adherence in 
the past may be more likely to be nonadherent during 
follow-up.
Covariates were also defined from the Health of the 
Nation Outcome Scale (HoNOS) instrument, taking the 
administration closest to the diagnosis date. HoNOS is 
a standard measure of patient wellbeing in UK mental 
health services, completed by clinicians after routine 
assessments,26,27 and whose validity has been assessed in 
a number of previous studies.26,28–30 HoNOS subscales 
measuring syndrome severity, other mental and physi-
cal health problems and functional status were included 
in this analysis. In addition, recorded diagnoses of opi-
ate or alcohol use disorders (diagnosed before or during 
the observation period) were also taken from structured 
fields and extracted from free text using the GATE appli-
cation described above. Diagnostic categories were based 
on the first SMI diagnosis received during the observa-
tion period. Further covariates were drawn from rou-
tinely completed fields in the source records including 
ethnic group and being married or cohabiting. Age was 
calculated on the diagnosis date.
Socioeconomic status was measured using area-level 
index of multiple deprivation which was calculated at 
the level of lower super output area for the residence: a 
UK address-grouping construct which contains an aver-
age of 1500 residents per area unit. The index of mul-
tiple deprivation incorporates several area-level domains 
defined from the (2001) national UK census (employ-
ment, income, education, health, barriers to housing and 
services, crime, living environment) with each domain 
given a weighting to reflect its importance. The address 
recorded closest to the time the individual entered the 
study cohort was used, with a separate category assigned 
to those who were homeless.31
Statistical analysis
Cohort members who were prescribed clozapine during 
the follow-up period were compared to never-exposed 
counterparts with respect to demographic and other risk 
factors for premature mortality. Kaplan–Meier curves 
with a log-rank test were used to compare those who 
were and were not prescribed clozapine. Having checked 
proportional hazards assumptions, Cox regression proce-
dures were used to model associations between clozapine 
and risk of all-cause mortality. Several different models 
were constructed where we controlled for sets of related 
covariates with the final model adjusting for all covari-
ates examined. The following sensitivity analyses were 
carried out: (1) excluding patients treated in one of the 4 
London boroughs (Lewisham) where data on clozapine 
exposure were less complete (unavailability of pharmacy 
dispensing data); (2) exclusion of those who were not tak-
ing any antipsychotics during the observation period and 
individuals with potentially lower adherence to treatment 
regimes (those who had received medication as LAI at any 
time in SLAM services or had been placed on a CTO); (3) 
restricting the sample to those with ICD-10 F20 schizo-
phrenia diagnosis; and (4) restricting the comparator 
group to individuals who were newly prescribed olanzap-
ine during the observation period (the clozapine group 
included 189 individuals who were newly prescribed both 
olanzapine and clozapine during the observation period); 
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(5) excluding those who came from outside the catchment 
(SLaM provides some national specialist services) in case 
these individuals had substantial contact with non-SLaM 
specialist care services which would not be represented 
on CRIS; (6) excluding those who were prescribed clo-
zapine for less than 30 days. We also investigated whether 
including inpatient and outpatient contact as separate 
covariates or as a combined variable made any difference 
to results.
We used standard propensity score methods for reduc-
ing the effects of confounding by indication in observa-
tional studies.32 The propensity score was defined as the 
probability of being treated with clozapine during the 
observation period based on a regression model which 
included factors relating to demographic and socioeco-
nomic status; diagnosis and severity of symptoms; men-
tal and physical health problems; substance use disorders 
and clinical monitoring (listed in table  1). We included 
the propensity score in place of these covariates in a Cox 
model. In addition we constructed a fully adjusted Cox 
model where we only included those at risk of being 
both treated and untreated by clozapine based on their 
propensity scores. Finally, Cox regression models were 
repeated for natural and unnatural causes of death as 
separate outcomes.
Results
Over the 5 year observation period we identified 14 754 
individuals (879 deaths) with a diagnosis of schizophre-
nia, schizoaffective disorder or bipolar disorder who met 
the inclusion criteria. The mean (SD) follow-up period 
was 1105 (571) days. Overall, 8.9% of follow-up days 
included face to face contact between patient and clini-
cian. The GATE application that was used to extract 
data on clozapine from electronic patient records was 
validated against manual record review resulting in preci-
sion (positive predictive value) and recall (sensitivity) for 
clozapine annotations of 96% and 92%, respectively, for 
“current use” (with a margin for error of 3 months with 
respect to the exact date the prescriptions was issued) and 
99% and 92% respectively for historical use (ie, having 
ever been prescribed clozapine). Among those prescribed 
clozapine the mean time over which they were prescribed 
this antipsychotic was 521.7  days SD 567.8. For 503 
people who were prescribed clozapine for at least 30 days 
the mean duration over which clozapine was prescribed 
was 774.4 days SD 533.4. It should be noted that some 
patients will have continued on clozapine after the obser-
vation period ended. Consequently, the time on clozapine 
reported in this analysis does not represent the full length 
of the time a patient may be placed on clozapine.
Table  1 provides numbers of cases and deaths by 
diagnosis, levels of symptom severity, and other cohort 
characteristics. A  quarter of service users included in 
the study were not prescribed any antipsychotics during 
follow-up (3860 individuals, 265 deaths). The majority of 
patients were prescribed some form of antipsychotic dur-
ing follow-up (10 894 individuals, 614 deaths) with 748 
individuals commencing clozapine during their follow-
up period, 15 of whom died. Among those diagnosed 
with schizophrenia, 6.5% were newly prescribed clozap-
ine during follow-up compared to 6.5% for schizoaffec-
tive disorder and 1.8% for bipolar disorder. Notably low 
numbers of deaths were recorded among those who were 
homeless (3.3%) and those who had ever been diagnosed 
with an opiate use disorder (3.5%); however these groups 
were younger than the remainder of the cohort and asso-
ciations with reduced risk of mortality were not signifi-
cant after adjusting for age.
The characteristics of those individuals with or with-
out clozapine exposure are compared in table  2. Those 
prescribed clozapine had higher levels of clinical contact, 
were more likely to be male, to be from a non-Caribbean 
black background, to have received schizophrenia as a 
first SMI diagnosis, and were younger [mean age (SD): 
36.7(12.7) vs 43.5(16.1) years]; they were significantly less 
likely to be in a relationship; to be from non-British white 
background and to have received a first SMI diagnosis 
of bipolar disorder. In addition, those prescribed clozap-
ine were significantly more likely to have poor functional 
status on the HoNOS scale (including problems with 
ADL impairment, occupational and recreational activi-
ties, social relationships, living conditions) and to have 
worse psychopathology (increased likelihood of having 
problems with overactive aggressive behavior, problems 
with hallucinations and delusions, subclinical depressed 
mood, minor problems with drinking or drug taking), 
or to have been diagnosed with an alcohol use disorder. 
Nine of the 15 patient characteristics associated with 
being prescribed clozapine were also significantly associ-
ated with an increased risk of mortality in age and gen-
der adjusted models (ie, being male, unmarried, having 
increased clinical contact, overactive aggressive behavior, 
minor depression, problems with drinking or drug tak-
ing, living conditions, ADLs and occupational or rec-
reational activities). The only characteristic associated 
with clozapine that was protective against mortality was 
younger age.
Figure  1 displays Kaplan–Meier curves comparing 
survival over time of those who were and were not pre-
scribed clozapine. Those prescribed clozapine displayed 
significantly better survival (p < .001). Moreover, Cox 
regression models displayed in table 3 indicated a strong 
association between clozapine exposure and reduced 
risk of all-cause mortality which remained significant 
and not substantially reduced in strength after adjusting 
for a range of potential confounders, including clinical 
monitoring. Adjustment for propensity scores, inclusion 
of inpatient and outpatient contact as separate variables 
or combined, and the previously specified sensitivity 
analyses made little difference to this finding. In fully 
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Table 1. Sample characteristics and percentage of deaths
Risk factors
N individuals
(N deaths) % deaths
Total 14 754 (879) 6.0
Taking clozapine during follow-up period
 No 14 006 (864) 6.2
 Yes 748 (15) 2.0
Taking any antipsychotic during follow-up period
 No 3860 (265) 6.9
 Yes 10 894 (614) 5.6
Demographic and socioeconomic factors
 Age (mean 43.2, SD 16.1, range 15–96 years)
 15 to < 35 years 5071 (67) 1.3
 35 to < 45 years 6461 (229) 3.5
 55 years and over 3222 (583) 18.1
 Gender
 Female 6769 (416) 6.2
 Male 7985 (463) 5.8
 Ethnicity
 White British 6106 (488) 8.0
 Other white background 1534 (100) 6.5
 South Asian 405 (16) 4.0
 East Asian 450 (22) 4.9
 Caribbean 1550 (105) 6.8
 Other Black background 3236 (97) 3.0
 Mixed, other or unknown 1473 (51) 3.5
 Married or cohabiting
 No 12 728 (757) 6.0
 Yes 2026 (122) 6.0
 Deprivation level in area of residence (tertiles)
 Low levels of deprivation 4495 (294) 6.5
 Medium levels of deprivation 4498 (264) 5.9
 High levels of deprivation 4512(261) 5.8
 Homeless 304 (10) 3.3
Diagnosis and severity of symptoms
 SMI Diagnosis
 Schizophrenia (ICD10 code - F20) 9437 (609) 6.5
 Schizoaffective disorder (ICD10 code - F25) 805 (43) 5.3
 Bipolar affective disorder (ICD10 code - F31) 4512 (227) 5.0
 Overactive, aggressive behavior
 Not a problem 6745 (388) 5.8
 Minor problems only 2636 (176) 6.7
 Significant problem 2558 (175) 6.8
Hallucinations and delusions
 Not a problem 5379 (321) 6.0
 Minor problems only 1821 (118) 6.5
 Significant problem 4675 (292) 6.3
 Depressed mood
 Not a problem 5268 (363) 6.9
 Minor problems only 3355 (226) 6.7
 Significant problem 3274 (144) 4.4
Additional mental and physical health problems
 Nonaccidental self-injury
 Not a problem 10 259 (670) 6.5
 Minor problem only 900 (41) 4.6
 Significant problem 756 (25) 3.3
 Problem-drinking or drug taking
 Not a problem 8798 (593) 6.7
 Minor problems only 1130 (48) 4.3
 Significant problem 1907 (95) 5.0
 Physical illness or disability problems
 Not a problem 7205 (174) 2.4
 Minor problems only 2003 (168) 8.4
 Significant problem 2701 (397) 14.7
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adjusted models for cause-specific mortality as an out-
come (table 4), the association remained significant and 
strong for reduced risk of mortality both from natural 
and unnatural causes.
Discussion
This is the first investigation to test the hypothesis that 
lower mortality in clozapine users is a result of inten-
sive clinical monitoring, and to describe the association 
of clozapine with both natural and unnatural mortal-
ity. Using electronic health record data from a compre-
hensive specialist mental health care service within a 
geographic catchment, we found no evidence that the 
reduced risk of mortality associated with clozapine was 
accounted for by clinical monitoring or other covariates. 
Individuals with SMI who were prescribed clozapine had 
more severe psychopathology (hallucinations, delusions, 
aggression, subclinical depression, addiction) and poorer 
functional status (problems with ADL impairment, occu-
pational and recreational activities, social relationships, 
living conditions). Nine of the 15 patient characteristics 
associated with being prescribed clozapine were them-
selves significantly associated with an increased risk of 
mortality in age and gender adjusted models. However 
despite this increased level of adversity those prescribed 
clozapine had substantially reduced risk of natural—and 
unnatural—mortality. These associations persisted after 
controlling for a broad range of potential confounders 
including contact with specialist mental health services, 
markers of disease severity, use of other antipsychotics, 
other aspects of mental and physical health and use of 
alcohol or other drugs. It was also robust to propensity 
score adjustment/sensitively analysis a method to reduce 
the effects of confounding by indication.32
In addition, excluding those who had been prescribed 
clozapine for less than 1 month increased the strength of 
association between clozapine and reduced risk of mor-
tality in individuals with SMI.
Our findings are consistent with other large epide-
miological cohort studies which have reported an asso-
ciation between clozapine and lower all-cause mortality. 
Amongst 67 000 clozapine-treated patients in the United 
States (1989 to 1996), all-cause mortality was lower dur-
ing the period of clozapine use than nonuse (HR 0.46).13 
Similarly, a more recent study conducted in Finland 
using record-based data on medication prescription (66 
881 SMI cases), found that clozapine was associated 
with the lowest mortality risk of all major antipsychot-
ics.15 However, in the above studies, a potential protective 
Risk factors
N individuals
(N deaths) % deaths
Functional status
 Activities of daily living (ADLs)
 Not a problem 5513 (188) 3.4
 Minor problems only 2780 (164) 5.9
 Significant problem 3574 (385) 10.8
 Standard of living conditions
 Not a problem 6966 (433) 6.2
 Minor problems only 2260 (146) 6.5
 Significant problem 2381 (146) 6.1
 Occupational and recreational activities
 Not a problem 5245 (283) 5.4
 Minor problems only 2768 (183) 6.6
 Significant problem 3609 (248) 6.9
 Social relationships
 Not a problem 4461 (287) 6.4
 Minor problems only 3138 (193) 6.2
 Significant problem 4249 (251) 5.9
Substance use disorders
 Ever diagnosed with alcohol use disorder
 No 13 492 (807) 6.0
 Yes 1262 (72) 5.7
 Ever diagnoses with opioid use disorder
 No 14 441 (868) 6.0
 Yes 313 (11) 3.5
Clinical monitoring (percentage of days in face-to-face 
contact with SLAM services during observation period, in 
tertiles)
 Low level of contact 4918 (260) 5.3
 Medium level of contact 4918 (293) 6.0
 High level of contact 4918 (326) 6.6
Table 1. (Continued)
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Table 2.  Characteristics of those individuals who were and were not prescribed clozapine during follow-up
N (%) of individuals
Risk factors Not prescribed clozapine Prescribed clozapine
Total 14 006 (100%) 748 (100%)
Demographic and socio-economic factors
 Age * mean(SD): 43.5(16.1)NC vs 36.7(12.7)C
 15 to < 35 years 4705 (33.6%) 366 (48.9%)
 35 to < 45 years 6150 (43.9%) 311 (41.6%)
 55 years and over 3151 (22.5%) 71 (9.5%)
 Gender*
 Female 6508 (46.5%) 261 (34.9%)
 Male 7498 (53.5%) 487 (65.1%)
 Ethnicity*
 White British 5813 (41.5%) 293 (39.2%)
 Other white background 1482 (10.6%) 52 (7.0%)
 South Asian 386 (2.8%) 19 (2.5%)
 East Asian 428 (3.1%) 22 (2.9%)
 Caribbean 1474 (10.5%) 76 (10.2%)
 Other Black background 3012 (21.5%) 224 (30.0%)
 Mixed, other or unknown 1411 (10.1%) 62 (8.3%)
 Married or cohabiting*
 No 12 033 (85.9%) 695 (92.9%)
 Yes 1973 (14.1%) 53 (7.1%)
 Deprivation level in area of residence (tertiles)
 Low levels of deprivation 4268 (32.5%) 228 (33.0%)
 Medium levels of deprivation 4266 (32.5%) 232 (33.6%)
 High levels of deprivation 4301 (32.8%) 211 (30.5%)
 Homeless 283 (2.2%) 21 (3.0%)
Diagnosis and severity of symptoms
 SMI Diagnosis*
 Schizophrenia (ICD10 code - F20) 8820 (63.0%) 617 (82.5%)
 Schizoaffective disorder (ICD10 code - F25) 753 (5.4%) 52 (7.0%)
 Bipolar affective disorder (ICD10 code - F31) 4433 (31.7%) 79 (10.6%)
 Overactive, aggressive behavior*
 Not a problem 6442 (57.2%) 303 (45.3%)
 Minor problems only 2454 (21.8%) 182 (27.2%)
 Significant problem 2374 (21.1%) 184 (27.5%)
Hallucinations and delusions *
 Not a problem 5225 (46.6%) 154 (23.1%)
 Minor problems only 1716 (15.3%) 105 (15.7%)
 Significant problem 4267 (38.1%) 408 (61.2%)
Depressed mood*
 Not a problem 4981(44.4%) 287 (43.0%)
 Minor problems only 3136 (27.9%) 219 (32.8%)
 Significant problem 3112 (27.7%) 162 (24.3%)
Additional mental and physical health problems
 Nonaccidental self-injury
 Not a problem 9688 (86.1%) 571 (85.7%)
 Minor problem only 847 (7.5%) 53 (8.0%)
 Significant problem 714 (6.4%) 42 (6.3%)
 Problem-drinking or drug taking*
 Not a problem 8335 (74.6%) 463 (70.0%)
 Minor problems only 1052 (9.4%) 78 (11.8%)
 Significant problem 1786 (16.0%) 121 (18.3%)
 Physical illness or disability problems
 Not a problem 6791 (60.4%) 414 (62.2%)
 Minor problems only 1880 (16.7%) 123 (18.5%)
 Significant problem 2572 (22.9%) 129 (19.4%)
Functional status
 Activities of daily living (ADLs)*
 Not a problem 5265 (47.0%) 248 (37.4%)
 Minor problems only 2618 (23.4%) 162 (24.4%)
 Significant problem 3321 (29.6%) 253 (38.2%)
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N (%) of individuals
Risk factors Not prescribed clozapine Prescribed clozapine
 Standard of living conditions*
 Not a problem 6610 (60.3%) 356 (55.4%)
 Minor problems only 2137 (19.5%) 123 (19.1%)
 Significant problem 2217 (20.2%) 164 (25.5%)
 Occupational and recreational activities*
 Not a problem 4995 (45.5%) 250 (38.8%)
 Minor problems only 2610 (23.8%) 158 (24.5%)
 Significant problem 3372 (30.7%) 237 (36.7%)
 Social relationships*
 Not a problem 4256 (38.1%) 205 (30.7%)
 Minor problems only 2968 (26.6%) 170 (25.5%)
 Significant problem 3957 (35.4%) 292 (43.8%)
Substance use disorders
 Ever diagnosed with alcohol use disorder*
 No 12 825 (91.6%) 667 (89.2%)
 Yes 1181 (8.4%) 81 (10.8%)
 Ever diagnoses with opiate use disorder
 No 13 703 (97.8%) 738 (98.7%)
 Yes 303 (2.2%) 10 (1.3%)
Clinical monitoring (percentage of days in face-to-face  
contact with SLAM services during observation period,  
in tertiles)*
 Low level of contact 4847 (34.6%) 71 (9.5%)
 Medium level of contact 4835 (34.5%) 83 (11.1%)
 High level of contact 4324 (30.9%) 594 (79.4%)
Notes: *P value < .05 for comparison between those who were and were not prescribed clozapine.
NC not prescribed clozapine during follow-up.
C prescribed clozapine during follow-up.
Fig. 1. Kaplan–Meier curves displaying the survival status of people with serious mental illness comparing those who were prescribed 
clozapine with those who were not (N = 14 754).
Table 2. (Continued)
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Table 3.  Multivariate Cox regression analyses of association between receiving clozapine treatment and all-cause mortality in 
individuals with serious mental illness.14 754 cases (879 deaths)
Prescribed clozapine during follow-up perioda Hazard ratio (95% CI) P values
Crude 0.3 (0.2–0.4) <.001
Adjusted for contact with SLAM servicesb 0.2 (0.1–0.3) <.001
Adjusted for contact with SLAM services,b
non-clozapine antipsychoticsc
socio-demographic factorsd
0.4 (0.2–0.7) .001
Adjusted for contact with SLAM services,b
non-clozapine antipsychoticsc
socio-demographic factors,d
SMI diagnosis and severitye
other mental & physical healthf
0.4 (0.2–0.7) .001
Adjusted for contact with SLAM services,b
non-clozapine antipsychoticsc
socio-demographic factors,d
SMI diagnosis and severitye
other mental and physical healthf
functional statusg
0.4 (0.2–0.7) .001
Fully adjustedh 0.4 (0.2–0.7) .001
Fully adjustedh
restricting to those taking any antipsychotics
0.4 (0.2–0.7) .001
Fully adjustedh
restricting to those with ICD-10 F20 Schizophrenia diagnosis
0.5 (0.3–0.8) .012
Fully adjustedh
excluding potentially noncompliant individuals (those  
who had received medication as depot or had placed on a  
supervised community treatment order at any time in  
SLAM services
0.3 (0.2–0.6) .001
Fully adjustedh
comparing to those who were newly prescribed  
olanzapine during follow-up
0.4 (0.2–0.8) .008
Fully adjustedh
excluding those referred in from outside the 4  
boroughs of the SLaM catchment
0.4(0.2–0.7) .002
Fully adjustedh
adjusting for inpatient and outpatient contact  
as separate covariates
0.4(0.2–0.7) .002
Fully adjustedh
including only those who were at risk of being both  
treated or untreated with clozapine (based on propensity scores)
0.4(0.2–0.7) .001
Adjusted by using propensity score as a covariate 0.3(0.2–0.5) <.001
Adjusted by using propensity score as a covariate,
excluding those who had been prescribed clozapine for less than 30 days
0.2(0.1–0.5) <.001
Notes: aFollow-up period begins at first diagnosis during observation window (from January 1, 2007 to December 31, 2011, inclusive) and 
end with death or end of observation window (whichever is sooner).
bPercentage of time during observation period where patient had face to face contact with SLAM services (measured as a continuous 
variable).
cUse of 1 or more antipsychotic other than clozapine.
dAge, gender, ethnicity, married or cohabiting, deprivation level in area of residence.
eSMI diagnosis, overactive aggressive behaviour, hallucinations and delusions, depressed mood.
fNonaccidental self-injury, problem drinking/drug taking, physical illness, or disability problems.
gImpairment in activities of daily living, standard of living conditions, occupational and recreational activities, social relationships.
hAll of above plus ever having had alcohol or opioid use disorder diagnoses.
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effect of the clinical monitoring required for clozapine 
treatment could not be excluded as a reason for lower 
mortality. Our own findings suggest that increased clini-
cal monitoring is not the reason for the lower mortality 
among those prescribed clozapine.
The association between clozapine and lower all-cause 
mortality was not purely attributable to lower suicide risk, 
as previously hypothesized.13,20 We discriminated between 
unnatural and natural cause mortality in our cohort of 
individuals with SMI and found, even after adjustment 
for a broad range of potential confounders, that clo-
zapine was associated with a lower risk of both natural 
and unnatural deaths. Our results contrast with findings 
of associations with increased risk of sudden cardiac 
death,9 respiratory related death,33 and potentially fatal 
metabolic34,35 and hematological disturbances.20 However, 
other studies indicate that clozapine may not confer addi-
tional cardiovascular risk or even be protective against 
cardiovascular related mortality compared to other anti-
psychotics.36,37 Our results do not exclude the possibly 
that clozapine may be associated with a higher risk of 
specific causes of death through individual pathways but 
do suggest that associations with lower risk of other mor-
tality may outweigh these.
This investigation has a number of strengths. The sam-
ple included all patients with SMI in contact with mental 
health services within a defined area over a 5-year period. 
In the United Kingdom, healthcare providers are legally 
required to keep death records up to date. Mortality trac-
ing in the source records system (updated monthly) is 
based on national certification so that only deaths occur-
ring outside the United Kingdom are likely to have been 
missed. We would expect our data to be representative 
of patients with SMI living in urban and suburban areas 
since SLAM is a near-monopoly provider of specialist 
mental healthcare for its geographic catchment. We drew 
on complete electronic clinical records for close to fifteen 
thousand cases, providing the statistical power to control 
for a range of potential confounders. The findings were 
also robust to a series of sensitivity analyses.
Limitations include the possibility of residual con-
founding, particularly medication use prior to the obser-
vation period.38 We only examined cases newly prescribed 
clozapine during the observation period and did not 
investigate mortality associations beyond 5 years. Despite 
our strategy of using propensity scores to perform sensi-
tivity analysis and adjustment sensitivity, confounding by 
indication is an important consideration which cannot be 
ruled out entirely in any observational study. However, we 
found no evidence to suggest that clinicians were reserv-
ing clozapine for patients who were healthier (apart from 
being younger). Instead, those individuals who were pre-
scribed clozapine had more severe psychopathology and 
poorer functional status (consistent with clozapine being 
a third line treatment). Consequently one would expect 
that the true association between clozapine and reduced 
mortality risk would be at least as strong or stronger than 
that which we observed. In addition we adjusted for indi-
cators of severity of illness including diagnosis, symp-
toms, physical illness, and functional status; however, a 
reliable assessment of duration of psychiatric illness was 
not available. Ultimately, the only means of excluding 
residual confounding is through randomized controlled 
trial evidence, which we do not believe is likely to be 
forthcoming to address this particular question.
Adverse lifestyle choices (other than drinking prob-
lems and opiate use), such as smoking, poor diet, and 
physical inactivity which may also contribute to the 
increased risk of  mortality in individuals with SMI38–41 
were not controlled for in this analysis, although it is 
not clear that those prescribed clozapine are likely to 
differ in these respects compared to people prescribed 
other antipsychotics. Also general practice data and glu-
cose or cholesterol data were not available for inclusion 
in this analysis. It is possible that the increased clinical 
contact received by those prescribed clozapine might 
provide greater opportunities for clinicians to influence 
the lifestyle choices of  their patients. However, this is 
unlikely to account for the association between clozap-
ine and reduced risk of  mortality, since this association 
Table 4. Multivariate Cox regression analyses of association between receiving clozapine treatment and cause-specific mortality in 
individuals with serious mental illness.
Hazard ratio (95% CI), p value
Prescribed clozapine during  
follow-up perioda
Natural causes of mortality
Deaths = 713
Unnatural causes of mortality
Deaths = 91
Crude 0.3 (0.1–0.5), p <.001 0.3 (0.1–1.4), p = .140
Fully adjustedb 0.5 (0.2–0.9), p = .022 0.2 (0.05–0.9), p = .039
Notes: aFollow-up period begins at first diagnosis during observation window (from January 1, 2007 to December 31, 2011, inclusive)  
and ends with death or end of observation window (whichever is sooner).
bAdjusted for percentage of time during observation period where patient had face to face contact with SLAM services (measured as a 
continuous variable); use of 1 or more antipsychotic other than clozapine; age; gender; ethnicity; married or cohabiting; deprivation level 
in area of residence; SMI diagnosis; overactive aggressive behaviour; hallucinations and delusions; depressed mood; non accidental self-
injury; problem drinking/drug taking; physical illness or disability problems; impairment in activities of daily living; standard of living 
conditions; occupational and recreational activities; social relationships; ever having had alcohol or opioid use disorder diagnoses.
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persisted after adjustment for level of  clinical contact. 
Specialist mental healthcare is provided at no cost to 
consumers as part of  the UK National Health Service 
(NHS), so the only missing mental health service con-
tacts would be from individuals seeking exclusively pri-
vate healthcare.37
The results of this investigation have important impli-
cations for clinical practice. Our results suggest that the 
observed protective effect of clozapine is not due to the 
extra clinical contact, as previously suggested, nor due 
to confounding by the broad range of other covariates 
that we examined. Clozapine appears to reduce the risk 
of both natural and unnatural mortality in patients with 
SMI. Current guidelines restricting the use of clozapine 
to those with treatment resistant SMI may need revising.
Acknowledgments
All the authors listed have made substantial contributions 
to: the process of hypothesis generation, data collection, 
statistical analyses, or interpretation of data; manuscript 
preparation; and given final approval to the manuscript. 
The corresponding author has access to reported and 
unreported data and has complete freedom to direct the 
analysis and reporting without influence, editorial direc-
tion or censorship from the sponsors.
Funding
This work was supported by the Clinical Records 
Interactive Search (CRIS) system funded and developed by 
the National Institute for Health Research (NIHR) Mental 
Health Biomedical Research Centre at South London and 
Maudsley NHS Foundation Trust and King’s College 
London and a joint infrastructure grant from Guy’s and St 
Thomas’ Charity and the Maudsley Charity (grant number 
BRC-2011–10035). Population Health Scientist Fellowship 
(grant number MR/J01219X/1). All other authors receive 
salary support from the National Institute for Health 
Research (NIHR) Mental Health Biomedical Research 
Centre at South London and Maudsley NHS Foundation 
Trust and King’s College London. The views expressed 
are those of the author(s) and not necessarily those of the 
NHS, the NIHR or the Department of Health.
RH, C-KC, RJ, HS, MB and RS have received research 
funding from Roche, Pfizer, J&J and Lundbeck. Other 
authors have no conflict of interest.
References
 1. Harris EC, Barraclough B. Excess mortality of mental disor-
der. Br J Psychiatry. 1998;173:11–53.
 2. Chang CK, Hayes RD, Broadbent M, et al. All-cause mor-
tality among people with serious mental illness (SMI), sub-
stance use disorders, and depressive disorders in southeast 
London: a cohort study. BMC Psychiatry. 2010;10:77.
 3. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital 
discharge for people with schizophrenia or bipolar disorder: 
retrospective study of linked English hospital episode statis-
tics, 1999–2006. BMJ. 2011;343:d5422.
 4. Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth 
for people with serious mental illness from a secondary mental 
health care case register in London, UK PloS ONE 2011;6.
 5. Hayes RD, Chang CK, Fernandes AC, et al. Functional sta-
tus and all-cause mortality in serious mental illness. PLoS 
One. 2012;7:e44613.
 6. Kilian R, Becker T, Krüger K, Schmid S, Frasch K. Health behav-
ior in psychiatric in-patients compared with a German general 
population sample. Acta Psychiatr Scand. 2006;114:242–248.
 7. Osborn DP, Nazareth I, King MB. Physical activity, dietary 
habits and Coronary Heart Disease risk factor knowledge 
amongst people with severe mental illness: a cross sectional 
comparative study in primary care. Soc Psychiatry Psychiatr 
Epidemiol. 2007;42:787–793.
 8. Roden DM. Drug-induced prolongation of the QT interval. 
N Engl J Med. 2004;350:1013–1022.
 9. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical 
antipsychotic drugs and the risk of sudden cardiac death. N 
Engl J Med. 2009;360:225–235.
 10. Stahl SM, Mignon L, Meyer JM. Which comes first: atypi-
cal antipsychotic treatment or cardiometabolic risk? Acta 
Psychiatr Scand. 2009;119:171–179.
 11. Crump C, Winkleby MA, Sundquist K, Sundquist J. 
Comorbidities and mortality in persons with schizophre-
nia: a Swedish national cohort study. Am J Psychiatry. 
2013;170:324–333.
 12. Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, et  al. 
Antipsychotics and mortality in first-onset schizophrenia: 
prospective Finnish register study with 5-year follow-up. 
Schizophr Res. 2013;150:274–280.
 13. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality 
in current and former users of clozapine. Epidemiology. 
1997;8:671–677.
 14. Hennen J, Baldessarini RJ. Suicidal risk during treatment with 
clozapine: a meta-analysis. Schizophr Res. 2005;73:139–145.
 15. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-
up of  mortality in patients with schizophrenia: a population-
based cohort study (FIN11 study). Lancet. 2009;374:620–627.
 16. Nielsen J, Kane JM, Correll CU. Real-world effectiveness 
of clozapine in patients with bipolar disorder: results from a 
2-year mirror-image study. Bipolar Disord. 2012;14:863–869.
 17. Kumra S, Kranzler H, Gerbino-Rosen G, et  al. Clozapine 
and “high-dose” olanzapine in refractory early-onset schizo-
phrenia: a 12-week randomized and double-blind compari-
son. Biol Psychiatry. 2008;63:524–529.
 18. Howes OD, Vergunst F, Gee S, et  al. Adherence to treat-
ment guidelines in clinical practice: study of antipsychotic 
treatment prior to clozapine initiation. Br J Psychiatry. 
2012;201:481–485.
 19. Cullen BA, McGinty EE, Zhang Y, et  al. Guideline-
concordant antipsychotic use and mortality in schizophrenia. 
Schizophr Bull. 2012.
 20. Meltzer HY. Clozapine: balancing safety with superior 
antipsychotic efficacy. Clin Schizophr Relat Psychoses. 
2012;6:134–144.
 21. Stewart R, Soremekun M, Perera G, et al. The South London 
and Maudsley NHS Foundation Trust Biomedical Research 
Centre (SLAM BRC) case register: development and descrip-
tive data. BMC Psychiatry. 2009;9:51.
 by guest on Septem
ber 2, 2014
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
Page 12 of 12
Hayes et al
 22. Hayes RD, Chang CK, Fernandes A, et  al. Associations 
between symptoms and all-cause mortality in individuals 
with serious mental illness J Psychosom Res. 2012;72:114–119
 23. Hayes RD, Chang CK, Fernandes A, et  al. Associations 
between substance use disorder sub-groups, life expectancy 
and all-cause mortality in a large British specialist mental 
healthcare service. Drug Alcohol Depend. 2011;118:56–61.
 24. World Health Organisation. Manual of the international sta-
tistical classification of diseases and realted health problems 10 
revision (ICD-10). 2000.
 25. Moncrieff  J, Thomas P, Crawford M, Henderson C. 
Modernising mental health services. Psychiatrists should 
oppose community treatment orders. BMJ. 1999;318:807.
 26. Wing JK, Beevor AS, Curtis RH, et al. Health of the Nation 
Outcome Scales (HoNOS). Research and development. Br 
J Psychiatry. 1998;172:11–18.
 27. Wing J, Curtis RH, Beevor A. Health of the Nation Outcome 
Scales (HoNOS). Glossary for HoNOS score sheet. Br 
J Psychiatry. 1999;174:432–434.
 28. Orrell M, Yard P, Handysides J, Schapira R. Validity and 
reliability of the Health of the Nation Outcome Scales 
in psychiatric patients in the community. Br J Psychiatry. 
1999;174:409–412.
 29. Pirkis JE, Burgess PM, Kirk PK, et al. A review of the psychometric 
properties of the Health of the Nation Outcome Scales (HoNOS) 
family of measures. Health Qual Life Outcomes. 2005;3:76.
 30. Hunter R, Cameron R, Norrie J. Using patient-reported out-
comes in schizophrenia: the Scottish Schizophrenia Outcomes 
Study. Psychiatr Serv. 2009;60:240–245.
 31. Noble M, McLennan D, Wilkinson K, et al. The English indi-
ces of deprivation 2007. London: Communities and Local 
Government; 2008.
 32. Austin PC. An introduction to propensity score methods for 
reducing the effects of confounding in observational studies. 
Multivar Behav Res. 2011;46:399–424.
 33. Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, 
Thomas A. Reasons for discontinuing clozapine: matched, 
case-control comparison with risperidone long-acting injec-
tion. Br J Psychiatry. 2009;194:165–167.
 34. Allison DB, Mentore JL, Heo M, et  al. Antipsychotic-
induced weight gain: a comprehensive research synthesis. Am 
J Psychiatry. 1999;156:1686–1696.
 35. Newcomer JW, Haupt DW. The metabolic effects of antipsy-
chotic medications. Can J Psychiatry. 2006;51:480–491.
 36. Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease 
mortality in patients with chronic schizophrenia treated with 
clozapine: a retrospective cohort study. J Clin Psychiatry. 
2010;71:304–311.
 37. Keown P, Mercer G, Scott J. Retrospective analysis of hos-
pital episode statistics, involuntary admissions under the 
mental health act 1983, and number of psychiatric beds in 
England 1996–2006. BMJ. 2008;337:a1837.
 38. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. 
Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 
2006;15:873–879.
 39. Robson D, Gray R. Serious mental illness and physi-
cal health problems: a discussion paper. Int J Nurs Stud. 
2007;44:457–466.
 40. Fagiolini A, Goracci A. The effects of undertreated chronic 
medical illnesses in patients with severe mental disorders.  
J Clin Psychiatry. 2009;70 Suppl 3:22–29.
 41. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy 
lifestyle of people with schizophrenia. Psychol Med. 
1999;29:697–701.
 by guest on Septem
ber 2, 2014
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
